Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580453358> ?p ?o ?g. }
- W2580453358 abstract "Therapeutic monoclonal antibodies [mAbs] have become molecules of choice to treat autoimmune disorders, inflammatory diseases and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells [T cell, natural killer (NK) cell or Macrophage cell] towards target cells have shown great potential to maximize the benefits of antibody therapy. In the past decade, many novel concepts to generate bispecific and multispecific antibodies have evolved successfully into a range of formats from full bispecific immunoglobulin gammas [IgGs] to antibody fragments. Impressively, antibody fragments such as bispecific T-cell engager [BiTE], bispecific killer cell engager [BiKE], trispecific killer cell engager [TriKE], tandem diabody [Tandab] and dual-affinity-retargeting [DART] are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells. Promisingly, Fc antigen binding fragment [Fcab] and monomeric antibody or half antibody may be particularly advantageous to target solid tumours owing to their small size and thus good tissue penetration potential while, on the other hand, keeping crystallizable fragment [Fc] related effector functions such as antibody-dependent cellular cytotoxicity [ADCC], complement-dependent cytotoxicity [CDC], antibody dependent cell-mediated phagocytosis [ADCP] and extended serum half-life via interaction with neonatal Fc receptor [FcRn]. This review, therefore, focuses on the progress of Fc engineering in generating bispecific molecules and on the use of small antibody fragment as scaffolds for therapeutic development." @default.
- W2580453358 created "2017-02-03" @default.
- W2580453358 creator A5003269740 @default.
- W2580453358 creator A5010398730 @default.
- W2580453358 creator A5044259899 @default.
- W2580453358 creator A5066326776 @default.
- W2580453358 date "2017-01-26" @default.
- W2580453358 modified "2023-10-18" @default.
- W2580453358 title "Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds" @default.
- W2580453358 cites W1502725684 @default.
- W2580453358 cites W1510837654 @default.
- W2580453358 cites W1526699428 @default.
- W2580453358 cites W1580407891 @default.
- W2580453358 cites W171521497 @default.
- W2580453358 cites W1840766718 @default.
- W2580453358 cites W1898469614 @default.
- W2580453358 cites W1921660070 @default.
- W2580453358 cites W1932781508 @default.
- W2580453358 cites W1943878720 @default.
- W2580453358 cites W1963778872 @default.
- W2580453358 cites W1968606358 @default.
- W2580453358 cites W1969482494 @default.
- W2580453358 cites W1971572485 @default.
- W2580453358 cites W1973134700 @default.
- W2580453358 cites W1975097310 @default.
- W2580453358 cites W1977743020 @default.
- W2580453358 cites W1981730803 @default.
- W2580453358 cites W1982622656 @default.
- W2580453358 cites W1982979599 @default.
- W2580453358 cites W1984707191 @default.
- W2580453358 cites W1988781661 @default.
- W2580453358 cites W1989731057 @default.
- W2580453358 cites W1992423971 @default.
- W2580453358 cites W1992612195 @default.
- W2580453358 cites W1992993067 @default.
- W2580453358 cites W1993530117 @default.
- W2580453358 cites W1993575340 @default.
- W2580453358 cites W1995374080 @default.
- W2580453358 cites W1995375939 @default.
- W2580453358 cites W1995543126 @default.
- W2580453358 cites W1996768467 @default.
- W2580453358 cites W1996820981 @default.
- W2580453358 cites W1998766772 @default.
- W2580453358 cites W2001483547 @default.
- W2580453358 cites W2003569476 @default.
- W2580453358 cites W2003630280 @default.
- W2580453358 cites W2006264959 @default.
- W2580453358 cites W2009179035 @default.
- W2580453358 cites W2010118863 @default.
- W2580453358 cites W2010264896 @default.
- W2580453358 cites W2013128795 @default.
- W2580453358 cites W2021084977 @default.
- W2580453358 cites W2021855052 @default.
- W2580453358 cites W2024737355 @default.
- W2580453358 cites W2024890197 @default.
- W2580453358 cites W2025779348 @default.
- W2580453358 cites W2026866389 @default.
- W2580453358 cites W2027014013 @default.
- W2580453358 cites W2030085576 @default.
- W2580453358 cites W2030522563 @default.
- W2580453358 cites W2030621571 @default.
- W2580453358 cites W2036987700 @default.
- W2580453358 cites W2037019703 @default.
- W2580453358 cites W2037318910 @default.
- W2580453358 cites W2038476799 @default.
- W2580453358 cites W2043048893 @default.
- W2580453358 cites W2045193638 @default.
- W2580453358 cites W2051944033 @default.
- W2580453358 cites W2053872195 @default.
- W2580453358 cites W2055348159 @default.
- W2580453358 cites W2055839516 @default.
- W2580453358 cites W2056362227 @default.
- W2580453358 cites W2059976588 @default.
- W2580453358 cites W2060974842 @default.
- W2580453358 cites W2072449326 @default.
- W2580453358 cites W2077069177 @default.
- W2580453358 cites W2079379157 @default.
- W2580453358 cites W2079595449 @default.
- W2580453358 cites W2085025484 @default.
- W2580453358 cites W2086146164 @default.
- W2580453358 cites W2088729407 @default.
- W2580453358 cites W2089873957 @default.
- W2580453358 cites W2090193152 @default.
- W2580453358 cites W2090810974 @default.
- W2580453358 cites W2091887204 @default.
- W2580453358 cites W2092048050 @default.
- W2580453358 cites W2093772830 @default.
- W2580453358 cites W2093797128 @default.
- W2580453358 cites W2094052190 @default.
- W2580453358 cites W2095553811 @default.
- W2580453358 cites W2098405656 @default.
- W2580453358 cites W2100410983 @default.
- W2580453358 cites W2103311193 @default.
- W2580453358 cites W2107925822 @default.
- W2580453358 cites W2111823261 @default.
- W2580453358 cites W2117131474 @default.
- W2580453358 cites W2121160430 @default.
- W2580453358 cites W2122006466 @default.
- W2580453358 cites W2123023182 @default.
- W2580453358 cites W2128545033 @default.